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Tetrahydrofolates (THF) are a family of cofactors that function as one-carbon donors in
folate-dependent one-carbon metabolism, a metabolic network required for the de novo
synthesis of purines, thymidylate, and for the remethylation of homocysteine to methion-
ine in the cytoplasm. 5-FormylTHF is not a cofactor in one-carbon metabolism, but serves
as a storage form of THF cofactors. 5-formylTHF is mobilized back into the THF cofactor
pool by methenyltetrahydrofolate synthetase (MTHFS), which catalyzes the irreversible
and ATP-dependent conversion 5-formyltetrahydrofolate to 5,10-methenyltetrahydrofolate.
Mthfs is not an essential gene in Arabidopsis, but MTHFS expression is elevated in animal
tumors, enhances de novo purine synthesis, confers partial resistance to antifolate purine
synthesis inhibitors and increases rates of folate catabolism in mammalian cell cultures.
However, the mechanisms underlying these effects of MTHFS expression have yet to be
established.The purpose of this studywas to investigate the role and essentiality ofMTHFS
in mice. Mthfs was disrupted through the insertion of a gene trap vector between exons
1 and 2. Mthfsgt/+ mice were fertile and viable. No Mthfsgt/gt embryos were recovered
from Mthfsgt/+ intercrosses, indicating Mthfs is an essential gene in mice.Tissue MTHFS
protein levels are decreased in both Mthfsgt/+ and Mthfs+/+ mice placed on a folate and
choline deﬁcient diet, and mouse embryonic ﬁbroblasts from Mthfsgt/+ embryos exhibit
decreased capacity for de novo purine synthesis without impairment in de novo thymidy-
late synthesis. MTHFS was shown to co-localize with two enzymes of the de novo purine
synthesis pathway in HeLa cells in a cell cycle-dependent manner, and to be modiﬁed
by the small ubiquitin-like modiﬁer (SUMO) protein. Mutation of the consensus SUMO
modiﬁcation sites on MTHFS eliminated co-localization of MTHFS with the de novo purine
biosynthesis pathway under purine-deﬁcient conditions.The results from this study indicate
that MTHFS enhances purine biosynthesis by delivering 10-formylTHF to the purinosome
in a SUMO-dependent fashion.
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INTRODUCTION
Tetrahydrofolates (THF) are a family of cofactors that carry and
chemically activate single carbons onN5,N10, or bridged between
N5 and N10 (Shane, 1995). THF cofactors contain a glutamate
polypeptide that contains 2–9 glutamate residues linked through
γ-peptide linkages (Shane, 1995). The glutamate residues serve
both to retain the co-factors within the cell and increase the afﬁn-
ity of folate-utilizing enzymes. THF cofactors donate or accept
one-carbons in a network of interconnected pathways referred to
as folate-mediated one-carbon metabolism (OCM). In the cyto-
plasm, folate-mediated OCM is required for the de novo synthesis
of purines, thymidylate, and for the remethylation of homocys-
teine tomethionine (Figure 1).Methionine canbe converted to the
methyl donor S-adenosylmethionine (AdoMet), which is a cofac-
tor for numerousmethylation reactions, including themethylation
of lipids, proteins, DNA, and RNA. Alterations in folate metabo-
lism are associated with several pathologies and developmental
anomalies including certain cancers (Suh et al., 2001) and neural
tube defects (Beaudin and Stover, 2009), but the mechanisms have
not been established. Impairments in OCM can result from pri-
mary folate deﬁciency,polymorphisms in genes that encode folate-
dependent enzymes, increased rates of folate degradation, and
secondary nutrient deﬁciencies including vitamin B6 or vitamin
B12. Biomarkers for impaired OCM include elevations in tissue
and serum homocysteine and S-adenosylhomocysteine (AdoHcy)
levels (Lindenbaum and Allen, 1995; Selhub, 1999; Ueland et al.,
2000; Yi et al., 2000), increased rates of uracil incorporation into
DNA which increases the incidence of DNA strand breaks (Blount
et al., 1997; Melnyk et al., 1999), and DNA hypomethylation (Yi
et al., 2000; Friso et al., 2002).
There are three THF cofactors that carry single carbons at
the oxidation level of formate: 10-formylTHF, 5-formylTHF, and
5,10-methenylTHF. These three forms of folate exist in chem-
ical equilibrium and slowly interconvert (Stover and Schirch,
1992). In the cell, 10-formylTHF is synthesized through the ATP-
dependent condensation of formate and THF catalyzed by the
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FIGURE 1 | Folate-dependent one-carbon metabolism in the
cytoplasm. Products of one-carbon metabolism are underlined; folate
cofactors are boxed. THF, tetrahydrofolate; MTHFS, methenyltetrahydrofolate
synthetase; SHMT1, serine hydroxymethyltransferase; GARFT, glycinamide
ribonucleotide formyltransferase; AICARFT, phosphoribosylaminoimidazole
carboxamide formyltransferase; TYMS, thymidylate synthase; dUMP,
deoxyuridine monophsophate. Hollow arrows represent reactions catalyzed
by MTHFD1.
10-formyltetrahydrofolate synthetase activity of the trifunctional
enzyme C1-tetrahydrofolate synthase (referred to as MTHFD1,
EC 1.5.1.5, 3.5.4.9, 6.3.4.3; Figure 1). 5,10-methenylTHF is
synthesized from 10-formylTHF both non-enzymatically and
through the cyclohydrolase activity of MTHFD1. 5-formylTHF
concentrations are regulated by a futile cycle involving ser-
ine hydroxymethyltransferase (SHMT, EC 2.1.2.1) and 5,10-
methenyltetrahydrofolate synthetase (MTHFS, EC 6.3.3.2; Stover
and Schirch, 1993). SHMT catalyzes the formation of 5-
formylTHF from 5, 10-methenylTHF, through a second catalytic
activity, whereas 5-formylTHF is mobilized back into the THF
cofactor pool through the activity of MTHFS, which catalyzes the
ATP-dependent conversionof 5-formylTHF to 5,10-methenylTHF
(Stover and Schirch, 1993; Figure 1).
The role of 5-formylTHF, and hence MTHFS, in mam-
malian OCM has not been fully established. 5-FormylTHF is
not an enzyme cofactor, but is a potent inhibitor of sev-
eral folate-dependent enzymes including aminoimidazolecarbox-
amide ribonucleotide formyltransferase (AICARFT, EC 2.1.2.3;
Bertrand and Jolivet, 1989) and SHMT (Stover and Schirch, 1991).
It has also been suggested to serve as a stable storage form of THF
in spores (Kruschwitz et al., 1994), but is not known to accumu-
late in mammalian cells. Whereas all cells contain SHMT, certain
prokaryotes lack MTHFS (Jeanguenin et al., 2010), and MTHFS is
not an essential gene in Arabidopsis (Goyer et al., 2005). In bacte-
ria, expression of prokaryotic glutamate formiminotransferases,
which are involved in folate-dependent histidine catabolism,
can functionally complement MTHFS activity by catabolizing
5-formylTHF (Jeanguenin et al., 2010). In mammalian cells, it
is not known if MTHFS activity is essential, or if mammalian
glutamate formiminotransferases are functionally redundant with
MTHFS activity.
Both 5-formylTHF and MTHFS have been shown to regulate
de novo purine biosynthesis. 10-formylTHF is the cofactor that
supplies the number 2 and 8 carbons for the de novo synthesis of
the purine ring, catalyzed by the enzymes AICARFT and glyci-
namide ribonucleotide formyltransferase (GARFT, EC 2.1.2.2),
respectively (Figure 1). Recently, the enzymes that constitute the
pathway for the de novo synthesis of purines were shown to form a
multi-enzyme complex referred to as the “purinosome” (An et al.,
2008).
Inhibition of MTHFS in MCF-7 cells impairs purine biosyn-
thesis in cultured cells (Bertrand and Jolivet, 1989), whereas over-
expression enhances rates of de novo purine biosynthesis (Field
et al., 2006). MTHFS binds10-formylTHF tightly (Field et al.,
2006); [6R,S]-10-FormylTHF tri-glutamates competitively inhibit
recombinant mouse MTHFS enzymatic activity with K i = 30 nM,
suggesting that 10-formylTHF is an effective in vivo inhibitor of
MTHFS activity (Field et al., 2006). Expression of MTHFS ele-
vates cellular 10-formylTHF levels in cultured cells (Girgis et al.,
1997), indicating that the MTHFS-10-formylTHF binary com-
plex is available for purine biosynthesis, and suggests that MTHFS
may function to deliver 10-formylTHF to the de novo purine
synthesis pathway (Field et al., 2006). Furthermore,MTHFS over-
expression in neuroblastoma confers resistance to the antifo-
late LY309887, a highly speciﬁc inhibitor that targets GARFT
and 10-formylTHF-dependent purine biosynthesis (Field et al.,
2009).
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In this study, the essentiality of MTHFS in mice was investi-
gated. This study is the ﬁrst examination of the effects of reduced
MTHFS expression in mice. The results demonstrate that Mthfs
is an essential gene in mice and that reduced MTHFS expres-
sion in mouse embryonic ﬁbroblast (MEF) cells is associated with
decreased capacity for de novo purine synthesis in these cells.
MTHFS haploinsufﬁciency did not affect tumorigenesis in the
Apcmin/+ model of sporadic intestinal tumor formation. Fur-
thermore, MTHFS is shown to associate with the “purinosome”
in mammalian cells, indicating that MTHFS enhances de novo
purine biosynthesis by delivering 10-formylTHF cofactors to the
purinosome.
MATERIALS AND METHODS
GENERATION OF Mthfsgt/+ MICE
All study protocols were approved by the InstitutionalAnimalCare
and Use Committee of Cornell University and conform to the
National Institutes of Health Guide for the Care and Use of Lab-
oratory Animals. Mouse embryonic stem cells containing a gene
trap vector between exon 1 and 2 of the mouse Mthfs gene were
purchased from Bay Genomics (San Fransisco, CA). Gene trap
vector pGT1LXF contains the engrailed 2 (En2) intron located
5′ of a βgeo cassette. Integration of the gene trap vector was
veriﬁed at Bay Genomics. Embryonic stem cells containing this
vector were injected in to C57Bl/6 blastocysts at the Cornell Uni-
versity Transgenic Mouse Core Facility (Ithaca, NY). Germ line
transmission of the Mthfsgt allele was conﬁrmed by PCR using
puriﬁed nuclear DNA, as described below. Mice were backcrossed
for 10 generations and maintained on C57Bl/6 background under
speciﬁc-pathogen free conditions.
GENOTYPING OF MTHFS DEFICIENT MICE
Genotyping was carried out using PCR from tail tissue nuclear
DNA that was isolated using the DNeasy DNA puriﬁcation kit
(Qiagen) per manufacturer’s instructions. A duplex PCR reac-
tion consisting of the following primers (priming sites shown in
Figure 2A) detected for the wild-type Mthfs allele and the Mthfsgt
allele:Mthfs forward, 5′-aggaatggcggcggtcacg-3′;Mthfs reverse, 5′-
gtctccttcctctgctacatcc-3′; RGT480,5′-ggcctccagacaagtagat-3′. PCR
conditions were 94˚C for 2min, followed by 30 cycles of 94˚C for
30 s, 61˚C for 30 s, 72˚C for 30 s, and a ﬁnal extension of 72˚C for
7min. The wild-type allele is detected as a 530 bp fragment and
the gene trap allele is detected as a 400 bp fragment (Figure 2B).
DIET STUDIES
Male Mthfsgt/+ and Mthfs+/+ mice were randomly assigned to
either the control (AIN-93G diet) or to the Modiﬁed AIN-3G diet
lacking folate and choline (folate/choline deﬁcient diet;Dyets, Inc.,
Bethlehem,PA) atweaning (3weeks of age).Miceweremaintained
on the diet for 5weeks. Mouse weight and food consumption were
monitored weekly. Food was removed from the cage 24 h prior to
sacriﬁce, after 12 h eachmouse was given one pellet of food to syn-
chronize intake. Mice were sacriﬁced another 12 h later by cervical
dislocation.
In order to determine whether reduced MTHFS expression
and a folate/choline deﬁcient diet modiﬁes intestinal cancer risk,
Mthfsgt/+ mice were mated with C57Bl/6-Apcmin/+ mice. F1
FIGURE 2 | Schematic of gene trap vector and PCR genotyping of
Mthfsgt allele. (A) Schematic of Mthfs gene, which consists of three exons.
The gene trap vector was inserted between exon 1 and 2. PCR priming
sites are shown with arrows. (B) PCR products (run on 2% agarose gel) for
nuclear tail DNA of Mthfs+/+ and Mthfsgt/+. The wild-type allele produces a
530 bp product and the gene trap (gt) allele produces a 400 bp product.
Apcmin/+/Mthfs+/+ and Apcmin/+/Mthfsgt/+ male mice were ran-
domly assigned to either the control or folate/choline deﬁcient
(FCD) diet. The mice remained on the diet for eleven weeks,
and were monitored and sacriﬁced as in the ﬁve week diet study
(described above). Genotyping of theApcmin allele was carried out
as previously described (Macfarlane et al., 2011).
TISSUE COLLECTION
Blood was collected by cardiac puncture into heparinized tubes.
Plasma was separated from red blood cells by centrifugation.
Brain, kidney and liver were removed, washed in cold phosphate-
buffered saline and snap frozen in liquid nitrogen. The colon was
removed, ﬂushed with cold phosphate-buffered saline, opened
longitudinally and cut into three sections and again washed in
cold phosphate-buffered saline before being snap frozen in liquid
nitrogen. All samples were stored at -80˚C.
MOUSE EMBRYONIC FIBROBLAST CULTURE
Mouse embryonic ﬁbroblasts were isolated from female Mthfsgt/+
mice bred to male Mthfsgt/+ mice at 10–14 days post coitus (dpc).
Brieﬂy, embryos were dissected from the uterus into cold ster-
ile PBS. The heads were taken for genotyping and the eviscer-
ated bodies were cut into 1–2mm pieces and digested in 0.05%
trypsin at 37ºC. Cells were cultured in alpha-minimal essen-
tial medium (alpha-MEM; Hyclone Laboratories) supplemented
with 10% fetal calf serum (Hyclone Laboratories), 0.1mM non-
essential amino acids (Gibco), 1mM sodium pyruvate (Gibco)
and penicillin/streptomycin (Gibco) and incubated at 37˚C in a
5% CO2 atmosphere.
WESTERN BLOT
Snap-frozen tissues or cell pellets were lysed in 10mM Tris,
pH 7.4, 150mM NaCl, 5mM EDTA, 5mM DTT, 1% Triton X-
100, and Mammalian Protease Inhibitor Cocktail (Sigma). Tis-
sue lysates were loaded onto 10% SDS-PAGE gels with 25μg
total protein/lane for MEF cells, kidney, liver, and colon samples
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and 50μg total protein/lane for brain samples [protein concen-
trations were determined using the Lowry–Bensadoun method
(Bensadoun and Weinstein, 1976)]. Proteins were then trans-
ferred to an immobilon-P PVDF membrane (Millipore). The
membrane was blocked overnight at 4ºC in phosphate-buffered
saline with 10% non-fat dry milk and 1% NP40. The membrane
was incubated at 4ºC overnight in a puriﬁed antibody (1:5,000
dilution) raised against murine MTHFS (peptide sequence NH+3 -
AKRGLRAELKQRLR-CO−2 ). After four washes of 10min each,
the membrane was incubated for 2 h in 1:20,000 HRP-conjugated
goat α-rabbit antibody (Pierce). After four washes of 10min each,
membranes were developed in SuperSignalWest Pico Chemilumi-
nescent Substrate (Pierce) and ﬁlms exposed. As a loading control,
membranes were also probed with an antibody to glyceraldehyde
3-phosphate dehydrogenase (GAPDH; Novus Biologicals) used at
1:40,000 dilution; HRP-conjugated goat α-mouse secondary anti-
body (Pierce) was used at 1:10,000 dilution. Images were digitized
and quantiﬁcation of protein expression was performed using
Image J software (NIH). For each given tissue, MTHFS expres-
sion was analyzed using a two-way ANOVA to assess differences
by genotype and diet; in MEF cell lysates, expression was analyzed
using a student’s t -test.
PURINE BIOSYNTHESIS ASSAY
This assay was carried out on eightMEF cell lines (n = 4Mthfs+/+,
n = 4 Mthfsgt/+) using methods detailed previously (Field et al.,
2006).
DETERMINATION OF PLASMA AND TISSUE FOLATE CONCENTRATION
Plasma and tissue folate concentrations were determined using the
Lactobacillus casei microbiological assay as previously described
(Suh et al., 2000).
dU SUPPRESSION
This assay was carried out on four MEF cell lines (n = 2 Mthfs+/+,
n = 2 Mthfsgt/+) using methods detailed previously (Macfarlane
et al., 2011).
EXPRESSION OF FLUORESCENT CONSTRUCTS IN HeLa CELLS
The human MTHFS cDNA (described in Girgis et al.,
1997) was ampliﬁed by PCR using forward primer 5′-
aatggcggcggcagcggtgag-3′and reverse primer 5′-gagctgttgacgagtct
tcgtaaaggac-3′, gel puriﬁed using a High Pure PCR Product
Puriﬁcation Kit (Roche) and inserted into the pcDNA3.1/CT-
GFP-TOPO®(Invitrogen) per manufacturer’s instructions. The
resulting vector, expressing human MTHFS-GFP (MTHFS
with a C-terminal GFP tag) was transfected into HeLa cells
using Lipofectamine 2000 (Invitrogen) per manufacturer’s
instructions. The MTHFS-K140R, K190R-GFP point mutants
were made using the QuikChange II Site-Directed Mutagen-
esis Kit (Stratagene) according to manufacturers’ instructions
using primers 5′-ccagtgaatgaaaacgacatgcgcgtagatgaagtcctttacg-3′
and 5′-cgtaaaggacttcatctacgcgcatgtcgttttcattcactgg-3′ (for K190R)
and primers 5′-ggccttgggtttgacaggcatggcaaccgaact-3′ and 5′-
agttcggttgccatgcctgtcaaacccaaggcc-3′ (for K140R). The sites of the
lysine to arginine mutations are underlined. Plasmids expressing
formylglycinamidine ribonucleotide fused to orange ﬂuorescent
protein (hFGAMS-OFP) and the trifunctional protein TrifGART
fused to orange ﬂuorescent protein (hTrifGART-OFP) were a
generous gift from Stephen Benkovic of The Pennsylvania State
University and have been described elsewhere (An et al., 2008).
HeLa cells were maintained in either purine-rich minimal
essential media alpha-modiﬁcation (αMEM, Hyclone) supple-
mented with 10% fetal bovine serum (FBS, Hyclone) for “purine-
rich” conditions or in Roswell Park Memorial Media (RPMI
1640, Hyclone) supplemented with 5% dialyzed FBS for “purine-
depleted” conditions. FBS was dialyzed against phosphate-
buffered saline with four buffer changes for a minimum of 24 h
at 4˚C, and then charcoal treated to remove any residual small
molecules.
CELL-CYCLE ARREST
HeLa cells maintained in purine-depleted media at 50% conﬂu-
ence were treated with either 60μM mevinolin (also known as
Lovastatin, Sigma) or 120 ng/mL nocodazole (Sigma) 24 h after
transfectionwithMTHFS-GFP (as described above).After another
24 h, cells were analyzed by confocal microscopy. To conﬁrm cell-
cycle arrest, cells were treated with Lipofectamine 2000 alone
(“mock”transfected) then treated 24 h laterwith cell cycle blocking
agents. Cells were analyzed by ﬂuorescence activated cell sorting
(FACS) 24 h after arrest.
FLUORESCENCE MICROSCOPY OF LIVE CELLS
HeLa cells were maintained in either purine-rich αMEM or
purine-depleted RPMI 1640 and transfected 48 h prior to visual-
ization. Confocal ﬂuorescencemicroscopy (Leica TCS SP2 system)
was used to image all cells at the Cornell Microscope and Imaging
Facility. Draq5 (Biostatus Limited) was used as a nuclear marker.
To visualizeMTHFS-GFP a 488 nm laser line andoptical ﬁlterwere
used. ForOFPandDraq5 the 543nmand633nm laser lines, respec-
tively, were used with a 543 nm/633 nm ﬁlter set. To ensure there
was no bleed over between channels, the images for each color
were taken sequentially and then merged in silico using Image J
software.
IN VITRO SUMOYLATION ASSAY
Puriﬁed recombinant mouse MTHFS was SUMOylated using the
SUMOlink SUMO-1 kit (Active Motif) according to manufac-
turer’s instructions. Reactions were analyzed via Western Blot
using either α-SUMO-1 (Active Motif) or α-MTHFS (described
above).
SUMO IMMUNOPRECIPITATION
MTHFS-GFP was transfected into HeLa cells maintained in
purine-deﬁcient RPMI-1640 using Lipofectamine 2000 (Invitro-
gen), as described above. Cells were trypsinized and collected via
centrifugation. Cells were lysed in Lysis Buffer (50mM Tris-HCl,
pH7.4, 150mM NaCl, 1% NP-40, 5mM EDTA) to which 5mM
DTT, protease inhibitor cocktail (Sigma) and 1mM SUMO pro-
tease inhibitorN-ethylmaleimide (NEM)were added. Cell extracts
(180μg/sample) were incubated with 4μg α-SUMO-1 antibody
(ActiveMotif) overnight at 4˚C.Dynabeads ProteinG (Invitrogen)
were used to pull downprotein complexes,whichwere elutedusing
1× SDS-PAGE sample buffer. Western Blot was then performed
as previously described.
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STATISTICAL METHODS
For animals studies in whichmice of both Mthfs+/+ and Mthfsgt/+
were placed onto either of two diets (control or folate/choline
deﬁcient) results were analyzed using a two-way ANOVA to assess
differences between genotype and diet and any possible gene-diet
interactions. For cell culture studies (dU suppression and purine
biosynthesis assay), a two-tailed student’s t -test was used to assess
differences between genotypes.
RESULTS
MTHFS NULL MICE ARE NOT VIABLE
Mthfsgt/+ mice were backcrossed onto a C57Bl/6 background
for 10 generations, and were viable and fertile. Mthfsgt/+ inter-
crosses yielded the expected frequency of Mthfs+/+ and Mthfsgt/+
pups, but did not yield Mthfsgt/gt pups in more than 100 live
births (data not shown). To determine if the lethality could be
rescued by maternal dietary purines, the drinking water of the
Mthfsgt/+ females was supplemented with 500μM hypoxanthine
during mating, and throughout pregnancy. No Mthfsgt/gt embryos
were observed at day 9.5 dpc in seven litters containing 42 fetuses
(Table 1), indicating that embryos homozygous for the Mthfsgt
allele did not survive early embryogenesis and that Mthfs is an
essential gene in C57Bl/6 mice.
The effect of Mthfs deletion on growth and food consumption
was determined over a 5week period. There were no signiﬁcant
differences in weight or food intake between Mthfsgt/+ and their
Mthfs+/+ littermates when fed the standard AIN93G diet (control
diet), or a modiﬁed AIN93G diet lacking folate and choline (FCD
diet; Figure 3).
MTHFS PROTEIN LEVELS IN Mthfsgt/+ MICE
Male Mthfsgt/+ mice were crossed to female C57Bl/6 mice to gen-
erate Mthfsgt/+ and Mthfs+/+ male mice which were randomly
assigned to either control or FCDdiet for 5-weeks.MTHFSprotein
levels are slightly, but not statistically signiﬁcantly, reduced in the
liver, kidney, and colon in Mthfsgt/+ animals placed on control diet
compared to wild-type animals on the same diet (Figures 4A,B).
Table 1 | Mthfs null mice are not viable and lethality is not rescued
with 500μM hypoxanthine supplementation to pregnant dams.
Genotype Expected
distribution
Observed
distribution
Mthfs+/+ 10.5 11
Mthfsgt/+ 21 31
Mthfsgt/gt 10.5 0
Litters observed 7
Mean litter size, including resorptions
(mean±SE)
8.1± 0.6
p value, observed versus expected
genotype distribution (1:2:1)
4.8× 10-4
Mthfsgt/+ mice were intercrossed and the progeny genotyped; the drinking water
for pregnant dams was supplemented with 500μM hypoxanthine. Expected
genotype distribution is based on Mendellian frequency, and differences from
expected distribution were analyzed using Chi square analysis.
FIGURE 3 |Weight gain and food intake in Mthfs+/+ and Mthfsgt/+ mice
fed either control diet (AIN-93G) or folate-choline deficient diet (FCD;
AIN-93G lacking folate and choline) for five weeks. In both (A) weight
gain per mouse and (B) intake per mouse Mthfs+/+ on control diet is shown
by squares; Mthfsgt/+ on control diet shown by triangles; Mthfs+/+ on FCD
shown by inverted triangles; Mthfsgt/+ on FCD shown by diamonds. Data is
shown as the mean and standard deviation with n= 10 per group.
Both Mthfsgt/+ and Mthfs+/+ mice placed on FCD diet exhibited
decreased MTHFS levels in these tissues compared to animals on
the control diet. Interestingly, MTHFS levels in both the kidney
and liver were reduced by more than 60% in animals placed on
the FCD relative to control diet (p< 0.01 for liver, and p= 0.02
for kidney) when densitomety values were analyzed using a two-
wayANOVA (data not shown).MTHFS protein levels in all tissues
were not signiﬁcantly different between Mthfsgt/+ and Mthfs+/+
mice placed on FCD diet.
Mthfsgt/+ MEFs DEMONSTRATE REDUCED DE NOVO PURINE
SYNTHESIS
The effect of Mthfs disruption on de novo purine biosynthesis rel-
ative to purine synthesis through the folate-independent salvage
pathway was determined in murine embryonic ﬁbroblasts isolated
fromMthfsgt/+ andMthfs+/+ embryos. In this assay [14C]-formate
is incorporated into purines via the folate-dependent de novo
purine synthesis pathway and [3H]-hypoxanthine is incorporated
via the purine salvage pathway, in which hypoxanthine is con-
verted to inosine monophosphate (IMP) and then to adenosine
and guanosine monophosphate in a folate-independent manner
(Yamaoka et al., 1997). Therefore, the ratio of 14C/3H in nuclear
DNA serves as a measure of the ability of de novo purine synthe-
sis to suppress contributions from the salvage pathway. As shown
in Figure 5, Mthfs+/+ MEFs displayed approximately two-fold
greater 14C/3H than Mthfsgt/+ cells (p< 0.05), indicating that cells
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FIGURE 4 |Western blot of Mthfs+/+ and Mthfsgt/+ tissues.Tissue
lysates from liver, kidney, colon (25μg total protein per lane), and brain
(50μg total protein per lane) were separated on a 10% SDS-PAGE gel.
Membranes were probed with sheep anti-mouse MTHFS antibody
(described in section Materials and methods). Glycerol aldehyde phosphate
dehydrogenase (GAPDH) was used as a loading control. (A)Three samples
per genotype and diet were run for colon, and this blot includes mouse
recombinant MTHFS (puriﬁed as described previously Anguera and Stover,
2006). (B)Two samples were run per genotype per diet for liver, kidney and
brain. (C) Cell lysates from Mthfs+/+ and Mthfsgt/+ MEF cells, n= 2 cell lines
per genotype.
with 50% reduced MTHFS expression (p< 0.05, Figure 4C) have
reduced de novo purine synthesis. Therefore, these data support
the previous ﬁnding that MTHFS expression enhances de novo
purine synthesis (Field et al., 2006).
Mthfsgt/+ MEFs DO NOT DEMONSTRATE ALTERED DE NOVO dTMP
SYNTHESIS.
The effect of Mthfs disruption on de novo thymidylate biosynthe-
sis relative to thymidine synthesis through the folate-independent
salvage pathway was determined in murine embryonic ﬁbrob-
lasts isolated from Mthfsgt/+ and Mthfs+/+ embryos. This assay
is similar to the formate suppression assay with the exception
that Mthfsgt/+ and Mthfs+/+ MEFs were incubated with [14C]-
deoxyuridine and [3H]-thymidine; deoxyuridine is incorporated
in thymidylate via the folate-dependent de novo synthesis pathway
and thymidine is incorporated via the salvage pathway (Oppen-
heim et al., 2001; Macfarlane et al., 2011). As shown in Figure 6,
there is no difference in de novo thymidylate synthesis capacity in
cells with reduced MTHFS expression.
FIGURE 5 | Mthfsgt/+ mouse embryonic fibroblasts (MEFs) exhibit less
efficient de novo purine biosynthesis. MEFs were isolated as described
in Section “Materials and methods” and cultured in the presence of
[3H]-hypoxanthine and [14C]-formate. [3H]-Hypoxanthine is converted to
purines via the folate-independent salvage pathway, whereas [14C]-formate
is incorporated into purines via the de novo pathway. The 14C/3H DPM ratio
was determined in nuclear DNA from two independent cell lines for both
Mthfs+/+ and Mthfsgt/+ genotypes. The 14C and 3H content (dpm) in resulting
fractions were quantiﬁed on a Beckman Coulter LS6500 Scintillation
Counter. Variation is expressed as standard deviation of the mean (two cell
lines per genotype), data were analysed using a student’s t -test.
FIGURE 6 | Mthfsgt/+ mouse embryonic fibroblasts (MEFs) do not
exhibit altered de novo thymidylate biosynthesis. MEFs were isolated
as described in Section “Materials and methods” and cultured in the
presence of [3H]-thymidine and [14C]-dUMP. [3H]-thymidine is converted to
thymidylate via the folate-independent salvage pathway, whereas
[14C]-dUMP is incorporated into thmidylate via the de novo pathway. The
14C/3H DPM ratio was determined in nuclear DNA from two independent
cell lines for both Mthfs+/+ and Mthfsgt/+ genotypes. The 14C and 3H content
(dpm) in resulting fractions were quantiﬁed on a Beckman Coulter LS6500
Scintillation Counter. Variation is expressed as standard deviation of the
mean (two cell lines per genotype), data were analysed using a student’s
t -test. dUMP, deoxyuridine monophosphate.
PLASMA OF Mthfsgt/+ MICE EXHIBITS ALTERED FOLATE LEVELS
The effect of MTHFS depletion on plasma and tissue folate con-
centrations were determined for Mthfsgt/+ and Mthfs+/+ mice.
Plasma folate levels were lower for animals on FCD at both
time points compared to animals fed the control diet (p< 0.001;
Tables 2 and 3). Mthfsgt/+ male mice exhibited a 14% reduction
in plasma folate compared to Mthfs+/+ mice on the control diet
at 5 weeks (p< 0.001; Table 2). Folate levels in liver, kidney, and
colon were lower in animals on FCD at 5-weeks (Table 2) and in
liver and colon after 11weeks (Table 3); there was no effect on
brain folate with the FCD, nor did Mthfs genotype inﬂuence folate
levels in liver, kidney, or colon (Tables 2 and 3).
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Table 2 | Folate levels of Mthfs+/+ and Mthfsgt/+ tissues after 5weeks on AIN-93G andAIN-93G lacking folate and choline.
Mthfs+/+ Mthfsgt/+
AIN-93G (C) Folate choline
deficient
AIN-93G (C) Folate choline
deficient
p value,
diet effect
p value,
genotype effect
p value,
gene×diet effect
Plasma 79.5± 4.7a 16.9± 3.2 68.0± 3.3 16.8± 0.4 < 0.001 <0.01 0.005
Liver 134.5± 27.3 56.1± 34.0 126.3± 22.1 23.6± 6.8 < 0.001 ns ns
Colon 40.2± 10.6 3.0± 1.4 34.9± 9.6 11.1± 4.4 < 0.001 ns ns
Kidney 56.1± 12.6 35.6± 6.7 47.4± 5.5 41.2± 10.9 < 0.05 ns ns
Brain 7.5± 0.7 5.0± 2.0 5.7± 2.0 4.6± 1.9 ns ns ns
Tissues values are represented as fmol folate/μg protein; plasma values represent ng folate/mL. Values expressed as mean±SD, n= 4; ns, not signiﬁcant.
aMthfs+/+ on control diet is signiﬁcantly different from Mthfsgt/+ on control diet and both genotypes on folate-choline deﬁcient diet by two-way ANOVA and Tukey’s
post-hoc test for genotype.
Table 3 | Folate levels of Mthfs+/+/Apcmin/+ and Mthfsgt/+/Apcmin/+ tissues after 11weeks on AIN-93G andAIN-93G lacking folate and choline.
Mthfs+/+/Apcmin/+ Mthfsgt/+/Apcmin/+
AIN-93G (C) Folate choline
deficient
AIN-93G (C) Folate choline
deficient
p value,
diet effect
p value,
genotype effect
p value,
gene×diet effect
Plasma 76.2± 5.0 8.2± 3.3 74.9± 13.5 14.2± 5.0 < 0.001 ns ns
Liver 127.5± 16.1 49.6± 11.5 133.5± 17.2 55.9± 11.5 < 0.001 ns ns
Colon 27.7± 2.9 2.5± 1.0 33.2± 6.6 6.3± 2.7 < 0.001 ns ns
Tissues values are represented as fmol folate/μg protein; plasma values represent ng folate/mL. Values expressed as mean±SD, n= 4–7; data were analyzed using
a two-way ANOVA; ns, not signiﬁcant.
Mthfs DISRUPTION DOES NOT MODIFY TUMOR DEVELOPMENT IN THE
Apcmin/+ MODEL
The effect of MTHFS disruption on intestinal tumor incidence
was determined by crossing Mthfsgt/+ and Mthfs+/+ mice to
the intestinal carcinogenesis model Apcmin/+ mice. Apcmin/+,
Mthfsgt/+ andApcmin/+,Mthfs+/+ miceweremaintained on either
the control or FCD diet for 11weeks. As shown in Table 4,
there were no differences in tumor number in the small intes-
tine nor the colon in Mthfsgt/+/Apcmin/+ mice compared to
Mthfs+/+/Apcmin/+ controls. The folate/choline deﬁcient diet did
notmodify total tumor number, and there were no genotype x diet
interactions (Table 4). Similarly, no genotype, diet, or genotype x
diet effects on tumor size (tumor area) were observed in either the
small intestine or colon (data not shown).
MTHFS CO-LOCALIZES WITH ENZYMES OF DE NOVO PURINE
SYNTHESIS
Recently, all the enzymes necessary for de novo purine synthesis
were found to co-localize to a multi-enzyme “purinosome” com-
plex under purine-depleted conditions (An et al., 2008). Two of
the enzymes in this complex, AICARFT and GARFT, require the
folate cofactor 10-formylTHF. Interestingly, the enzyme responsi-
ble for the synthesis of 10-formylTHF, C1-THF synthase, is not
a part of the “purinosome,” suggesting that another protein is
Table 4 | Tumor number in small intestine and colon of and Mthfs+/+/Apcmin/+ Mthfsgt/+/Apcmin/+ after 11weeks on AIN-93G andAIN-93G
lacking folate and choline.
Mthfs+/+/Apcmin/+ Mthfsgt/+/Apcmin/+
AIN-93G (C) Folate choline
deficient
AIN-93G (C) Folate choline
deficient
p value,
diet effect
p value,
genotype effect
p value,
gene×diet effect
Small intestine 18.5± 3.1 18.6± 1.5 17.0± 1.4 17.1± 1.1 ns ns ns
Colon 0.8± 0.3 1.2± 0.4 0.8± 0.2 1.0± 0.3 ns ns ns
Values expressed as mean±SEM of total small intestine tumor number and total colon tumor number, n= 10–13; data were analyzed using a two-way ANOVA; ns,
not signiﬁcant.
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required to deliver 10-formylTHF to the complex. To test our
hypothesis that MTHFS functions to provide 10-formylTHF for
de novo purine biosynthesis (Field et al., 2006, 2009), the local-
ization of MTHFS within the “purinosome” was investigated in
HeLa cells. As shown in Figures 7A–C, MTHFS-GFP expression
is diffuse throughout the cytoplasm and nucleus of cells main-
tained in purine-rich αMEM. However, in cells maintained in
purine-depleted media (Figures 7D–F), MTHFS-GFP expression
is clustered in the cytoplasm of approximately 50% of observed
cells. Since this clustering mimicked the clustering of the “puri-
nosome,” MTHFS-GFP was co-expressed with hFGAMS-OFP or
hTrifGART-OFP (GARFT) under purine-depleted conditions. As
shown in Figure 8,MTHFS-GFP is found in the same cytoplasmic
cluster as both hFGAMS-OFP and hTrifGART-OFP. These data
demonstrate that MTHFS is a component of the purinosome and
may function to deliver 10-formylTHF to this complex.
SUMO MODIFICATION TARGETS MTHFS TO THE “PURINOSOME”
COMPLEX
The MTHFS primary sequence contains two conserved SUMO
modiﬁcation sites at residues K140 and K190. Recombinant
murine MTHFS was shown to be a substrate for sumoyla-
tion in vitro using the SUMOlink SUMO-1 kit (Active Motif;
Figure 9). To determine if MTHFS is sumoylated in vivo, an
immunoprecipitation with α-SUMO1 antibody was performed
in extracts from cells transfected with constructs expressing either
MTHFS-GFP or MTHFS-K140R, K190R-GFP. Signiﬁcantly less
MTHFS-K140R, K190R-GFP protein was immunoprecipitated
compared to MTHFS-GFP protein (Figure 10), indicating that
K140 and/or K190 are SUMO modiﬁed in HeLa cells, but that
additional MTHFS lysine(s) are SUMO modiﬁed other than K140
and K190.
To determine if MTHFS sumoylation was essential for its
co-localization with the purinosome, the MTHFS-K140R,K190R-
GFP fusion protein was expressed in Hela cells maintained in
both purine-rich and purine-depleted media. Mutation of K140
and K190 ablated the clustering of MTHFS-GFP under purine-
depleted conditions (Figures 11C,D). MTHFS-K140R, K190R-
GFP remained diffuse throughout the cytoplasm and nucleus
under both purine-rich (Figures 11A,B) and purine-depleted
conditions (Figures 11C,D), whereas the control MTHFS-GFP
formed punctuate clusters under purine-deﬁcient conditions
(Figures 11E,F). This suggests that sumoylation of MTHFS at
K140 and/or K190 is required for the formation of the punctuate
clusters and localization of MTHFS to the “purinosome.”
FORMATION OF “PURINOSOME” CLUSTERS IS ABOLISHED BY
ADDITION OF ADENOSINE OR GUANOSINE TO DEPLETED MEDIA
Theoriginal experiments describing the identiﬁcationof the“puri-
nosome”were carried out in“purine-depleted RMPI-1640”media
(An et al., 2008) that lacked not only purine bases, but all nucle-
osides and nucleotides. To ensure that the formation of these
clusters was purine-speciﬁc, the“purine-depleted”media was sup-
plemented with either 10mg/L adenosine or 10mg/L guanosine
(concentration of nucleosides in the control purine replete media
αMEM).Addition of either purine base resulted in diffuse localiza-
tion of MTHFS-GFP throughout the cells (Figure 12). Addition
of cytosine and uridine to the culture medium at a concentra-
tion of 10mg/L did not perturb “purinosome” cluster formation
(Figure 12).
THE “PURINOSOME” FORMS DURING G1 PHASE OF THE CELL CYCLE
In purine-depletedmedia, roughly 50%of the cells on a given plate
exhibit “purinsome” cluster formation. To determine whether
“purinosome” formation was cell cycle regulated, we arrested cells
FIGURE 7 | MTHFS-GFP forms clusters in purine-depleted media.The MTHFS-GFP fusion protein was expressed in HeLa cells maintained in either
purine-rich αMEM medium (A–C) or purine-depleted RPMI-1640 medium (D–F) as described in Section “Materials and methods.” Nuclear DNA stain in red
(DRAQ5) and MTHFS-GFP is green.
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FIGURE 8 | MTHFS-GFP co-localizes with hTrifGART-OFP and hFGAMS-OFP under purine-depleted conditions. Fluorescent fusion proteins were
expressed in HeLa cells maintained in purine-deﬁcient RPMI as described in Section “Materials and methods.” (A) hMTHFS-GFP fusion protein, (B)
hFGAMS-OFP fusion protein, (C) merge of (A) and (B). (D) hMTHFS-GFP fusion protein, (E) hTrifGART-OFP fusion protein, (F) merge of (D) and (E); nuclear
stain (DRAQ5) shown in blue.
FIGURE 9 | MTHFS is sumoylated in vitro. Puriﬁed recombinant mouse
MTHFS was SUMOylated using the SUMOlink SUMO-1 kit (Active Motif)
according to manufacturer’s instructions. Membranes were probed with
1:5,000 dilution of sheep anti-mouse MTHFS antibody (described in section
Materials and methods) or 1:10,000 α-SUMO1 antibody (ActiveMotif).
maintained in purine-depleted media at G1-phase with lovastatin
or at G2/M with nocodazol 24 h after transfection with MTHFS-
GFP. Cell-cycle arrest was conﬁrmed by FACS (data not shown).
In cells arrested in G1-phase, nearly 90% of observed cells exhib-
ited “purinosome” formation (Figures 13A,B). We were unable
FIGURE 10 | Sumo Immunoprecipitation.The MTHFS-GFP fusion protein
was expressed in HeLa cells maintained in purine-deﬁcient RPMI-1640
using Lipofectamine 2000 (Invitrogen), as described above. Mock
transfection contained only Lipofectamine 2000. Cell extracts
(180μg/sample) were incubated with 4μg α-SUMO-1 antibody (Active
Motif) overnight at 4˚C. Dynabeads Protein G (Invitrogen) were used to pull
down protein complexes, which were eluted using 1×SDS-PAGE sample
buffer and resolved on a 12% SDS-PAGE acrylamide gel. Membranes were
probed with 1:5,000 dilution of sheep anti-mouse MTHFS antibody
(described in section Materials and methods).
to identify any cells with clustered MTHFS-GFP in the G2/M
arrested cells (Figures 13C,D). These observations suggest that the
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FIGURE 11 | Sumoylation of MTHFS at K140 and/or K190 is required for
clustering under purine-deficient conditions. MTHFS-K140R, K190R-GFP
fusion proteins were expressed in HeLa cells and visualized by confocal
microscopy as described in Section “Materials and methods.” (A, B)The
MTHFS-K140R, K190R-GFP fusion protein in purine-rich αMEM; (C, D)The
MTHFS-K140R, K190R-GFP fusion protein in purine-depleted RPMI-1640; (E,
F)The MTHFS-GFP fusion protein in “purine-depleted” RPMI-1640. Nuclear
stain (DRAQ5) shown in blue.
“purinosome”forms primarily duringG1-phase of the cell cycle, as
has been suggested previously (An et al., 2008). Since nocodazole
disrupts microtubule polymerization, these data are consistent
with the observation that “purinosome” formation requires intact
microtubules (An et al., 2010a).
DISCUSSION
Homozygous disruption of Mthfs is embryonic lethal prior to
embryonic day 9.5 (Table 1), indicating that MTHFS is an essen-
tial gene in mice. Mthfsgt/+ mice are viable and fertile and do
not show any difference in weight gain nor food intake, com-
pared to wild-type littermates (Figure 3). This result contrasts
what was reported for Arabidopsis, where MTHFS is not essen-
tial (Goyer et al., 2005). The differences in the essentiality of
MTHFS between species may result from differences in the abil-
ity of glutamate formiminotransferase to functionally compensate
for MTHFS activity. Alternatively, MTHFS may only be essential
in organisms, like mammals, that are not capable of folate biosyn-
thesis and therefore cannot tolerate the accumulation of a single
folate vitamer, including 5-formylTHF.
MTHFS enzymatically converts 5-formylTHF, a stable storage
form of folate, to 5,10-methenylTHF, which is a metabolically
active form of folate (Figure 1). Interestingly, MTHFS protein
levels were more than 60% lower in liver and kidney tissues of
animals placed on the FCD diet (Figure 4). Given that tissue
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FIGURE 12 | Formation of punctuate “purinosome” clusters is
abolished by addition of adenosine and guanosine to media.The
MTHFS-GFP protein was expressed in HeLa cells and visualized by confocal
microscopy as described in Section “Materials and methods.” Cells were
cultured with either purine-rich α-MEM (A, B), purine-depleted RPMI-1640
(C, D), or purine-depleted RPMI-1640 supplemented with individual
nucleosides. The nucleosides were added at 10mg/L, the concentration at
which they are present in the purine-rich α-MEM. Pyrimidine nucleosides
uridine and cytosine were added together (E, F). Purine nucleosides
adenosine (G, H) and guanosine (I, J) were added individually.
FIGURE 13 | MTHFS-GFP forms clusters in purine-depleted media
during G1-phase of the cell cycle.The MTHFS-GFP fusion protein (shown
in green) was expressed in HeLa cells maintained in either purine-depleted
RPMI-1640 medium as described in Section “Materials and methods.” 24 h
prior to visualization, cells were treated with 60μM mevinolin (lovastatin) to
arrest in G1-phase (A, B) or 120 ng/mL nocodazole to arrest at G2/M (C, D).
Cell-cycle arrest was conﬁrmed by FACS.
folate levels were reduced signiﬁcantly when animals were placed
on the FCD diet (Tables 2 and 3) and that elevated MTHFS
expression in cell culture models has been shown to increase rates
of folate catabolism (Anguera et al., 2003), we hypothesize that
MTHFS expression may be downregulated in response to folate
deﬁciency to protect cellular folate pools. Furthermore, MTHFS
protein levels were not signiﬁcantly decreased in tissues from
Mthfsgt/+ animals relative to wild-type littermates, suggesting that
MTHFS levels may be upregulated in a post-transcriptional or
post-translational fashion. A similar phenomenon was observed
inN-ethyl-N-nitrosourea (ENU)mutagenizedmicewith an amino
acid substitution in the thymidylate synthase (TYMS) gene (Ching
et al., 2010).
Mthfsgt/+ mice are not more susceptible than Mthfs+/+ mice
to tumorigenesis when when crossed to C57Bl/6-Apcmin/+ mice
(Table 4), a model of spontaneous intestinal neoplasia (Taketo
and Edelmann, 2009). Neoplastic tissues cannot effectively salvage
purines, and therefore rely more heavily than normal tissue on the
de novo purine synthesis pathway (Jackson and Harkrader, 1981;
Habeck et al., 1994;McGuire, 2003), andMthfsgt/+ MEFs exhibited
decreased de novo purine synthesis capacity relative to the salvage
pathway (Figure 5). However, because MTHFS protein levels did
not differ between Mthfsgt/+ and Mthfs+/+ on the FCD diet, we
cannot make conclusions regarding the role of MTHFS activity as
a modiﬁer of carcinogenesis in the Apcmin/+ model.
Mthfsgt/+ MEFs exhibit a 50% decrease in the efﬁciency of
de novo purine biosynthesis relative to wild-type mice, suggest-
ing that MTHFS may be essential for de novo purine biosynthesis.
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This ﬁnding is consistent with previous results of cell culturemod-
els that demonstrate increased MTHFS expression enhances de
novo purine biosynthesis relative to the purine salvage pathway
(Field et al., 2006). Furthermore, MTHFS expression in neu-
roblastoma has been shown to decrease the cytotoxicity of the
purine-speciﬁc chemotherapeutic antifolate LY309887 (Field et al.,
2009). However, the mechanism whereby MTHFS stimulates de
novo purine biosynthesis and protects the pathway from antifolate
inhibitors has remained elusive. The recent discovery that all six
enzymes required for de novo purine synthesis co-localize during
purine depletion, and the observation in this study that MTHFS-
GFP co-localizes with two ﬂuorescently tagged enzymes of the de
novo purine synthesis pathway, hFGAMS-OFP and hTrifGART-
OFP under purine-deﬁcient conditions (Figures 7 and 8) suggests
that MTHFS delivers the chemically labile 10-formylTHF to this
“purinosome” complex and protects the complex from antifo-
late inhibitors. This observation is particularly interesting given
that the enzyme responsible for the synthesis of 10-formylTHF,
C1-THF Synthase, is not part of the “purinosome” (An et al.,
2008, 2010b). The co-localization of MTHFS with the “puri-
nosome” sheds light onto the mechanism by which the tight
binding of 10-formylTHF to MTHFS results in enhanced de
novo purine synthesis; the 50% reduction in the efﬁciency of
de novo purine biosynthesis in Mthfsgt/+ MEFs indicates that
MTHFSand10-formylTHFmaybe rate limiting fordenovo purine
biosynthesis.
These data also demonstrate that MTHFS localization to the
“purinosome”complex is dependent onMTHFS sumoylation. The
small ubiquitin-related modiﬁer (SUMO, NP_001005781) is a 10
kDa protein that covalently attaches to lysine residues primar-
ily, but not exclusively, in KxE motifs (where  is a hydrophobic
amino acid,K is the lysine that ismodiﬁed and x is any amino acid).
This process is facilitated by several enzymes: AOS1/UBA2, the
E1 activating enzyme; UBC9, the E2 conjugating enzyme, which
recognizes the acceptor site on the target protein; E3 ligase. Sumoy-
lation has been shown to both enhance and inhibit protein-protein
interactions andplays an essential role in the intracellular targeting
of proteins (Geiss-Friedlander and Melchior, 2007). For instance,
the folate-dependent enzymes of the thymidylate cycle have been
shown to localize to the nucleus in a sumoylation-dependent fash-
ion during S-phase of the cell cycle (Woeller et al., 2007). In this
study, MTHFS is shown to be sumoylated in both an in vitro
sumoylation assay (Figure 9) and in HeLa cell transfected with
MTHFS-GFP (Figure 10). Mutation of lysine to arginine on the
twopotential SUMOmodiﬁcation sites results in impaired sumoy-
lation in HeLa cells (Figure 10). Interestingly, MTHFS did not
form clusters under purine-deﬁcient conditions when K140 and
K190 were mutated to arginine (Figure 11), demonstrating that
sumoylation at either or both of these sites is required for com-
plex formation and may enhance the protein-protein interactions
underlying the assembly of this complex.
MTHFS-GFP was shown to localize with the “purinosome”
in nucleotide/nucleoside-deﬁcient RPMI-1640 media as in the
original reports identifying the “purinosome” (An et al., 2008,
2010b). Nucleotide supplementation demonstrated that MTHFS-
GFP was only associated with the purinosome when exogenous
purines were not available; MTHFS-GFP did not form clusters
when purine nucleosides (adenosine or guanosine) were added to
the media (Figure 12). Conversely, addition of pyrimidines (uri-
dine and cytidine) to the culturemediumdidnot impair formation
of “purinosome” with MTHFS-GFP (Figure 12). Furthermore,
localization of MTHFS-GFP to “purinosome” clusters occurs in
cells arrested in G1-phase of the cell cycle (Figures 13A,B), but
not in cells arrested at the G2/M transition (Figures 13C,D). This
is consistent with the observation that “purinosomes” formation
is reversible and responds to cellular demands for nucleotides
required to meet energetic needs and to maintain balanced
nucleotide pools for DNA replication during S-phase and for the
G1/S transition (Kondo et al., 2000; Mathews, 2006; An et al.,
2008). Taken together, the data presented further support the
suggestion that MTHFS responds to reduced intracellular purine
levels presumably by delivering 10-formylTHF to the enzymes
of de novo purine synthesis that require this co-factor, GARFT
and AICARFT.
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